Handel Lexicon - LXRX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.05 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Lexicon Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Tidligere luk* | 2.72 |
Åben* | 2.67 |
1-Års Ændring* | 50% |
Dagens Spænd* | 2.44 - 2.67 |
52-Ugers Spænd | 1.31-3.79 |
Gennemsnitlig Volumen (10 dage) | 5.05M |
Gennemsnitlig Volumen (3 måneder) | 29.81M |
Market Cap | 520.35M |
P/E-forhold | -100.00K |
Udestående aktier | 244.85M |
Omsætning | 126.00K |
EPS | -0.63 |
Dividend (Udbytte %) | N/A |
Beta | 1.27 |
Næste indtjeningsopgørelse | Jul 31, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 2.72 | -0.03 | -1.09% | 2.75 | 2.77 | 2.64 |
Jun 1, 2023 | 2.68 | 0.00 | 0.00% | 2.68 | 2.70 | 2.54 |
May 31, 2023 | 3.27 | 0.39 | 13.54% | 2.88 | 3.39 | 2.87 |
May 30, 2023 | 2.86 | -0.52 | -15.38% | 3.38 | 3.43 | 2.65 |
May 26, 2023 | 3.14 | 0.12 | 3.97% | 3.02 | 3.20 | 2.90 |
May 25, 2023 | 2.86 | -0.17 | -5.61% | 3.03 | 3.03 | 2.83 |
May 24, 2023 | 2.98 | -0.04 | -1.32% | 3.02 | 3.02 | 2.94 |
May 23, 2023 | 3.02 | -0.16 | -5.03% | 3.18 | 3.27 | 3.02 |
May 22, 2023 | 3.17 | 0.10 | 3.26% | 3.07 | 3.27 | 3.03 |
May 19, 2023 | 2.97 | 0.04 | 1.37% | 2.93 | 3.00 | 2.86 |
May 18, 2023 | 2.86 | -0.04 | -1.38% | 2.90 | 2.91 | 2.76 |
May 17, 2023 | 2.89 | -0.04 | -1.37% | 2.93 | 2.94 | 2.84 |
May 16, 2023 | 2.90 | -0.03 | -1.02% | 2.93 | 2.95 | 2.81 |
May 15, 2023 | 2.94 | 0.06 | 2.08% | 2.88 | 3.01 | 2.84 |
May 12, 2023 | 2.83 | -0.29 | -9.29% | 3.12 | 3.16 | 2.81 |
May 11, 2023 | 3.10 | 0.06 | 1.97% | 3.04 | 3.17 | 2.98 |
May 10, 2023 | 3.03 | -0.13 | -4.11% | 3.16 | 3.16 | 2.91 |
May 9, 2023 | 3.00 | -0.24 | -7.41% | 3.24 | 3.24 | 2.96 |
May 8, 2023 | 3.23 | -0.27 | -7.71% | 3.50 | 3.53 | 3.20 |
May 5, 2023 | 3.45 | 0.36 | 11.65% | 3.09 | 3.75 | 3.05 |
Lexicon Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
Monday, July 31, 2023 | ||
Tid (UTC) (UTC) 10:59 | Land US
| Begivenhed Q2 2023 Lexicon Pharmaceuticals Inc Earnings Release Q2 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Tuesday, November 7, 2023 | ||
Tid (UTC) (UTC) 10:59 | Land US
| Begivenhed Q3 2023 Lexicon Pharmaceuticals Inc Earnings Release Q3 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total omsætning | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
Omsætning | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
Kost af omsætning, Total | 0 | 0 | 1.929 | 3.231 | 2.491 |
Bruttofortjeneste | 0.139 | 0.298 | 22.066 | 318.842 | 60.718 |
Totale Driftsudgifter | 100.899 | 87.388 | 70.792 | 180.628 | 166.488 |
Salgs/Generelle/Admin. Udgifter, Total | 48.083 | 32.342 | 47.23 | 56.835 | 63.754 |
Forskning & Udvikling | 52.816 | 55.046 | 153.621 | 91.924 | 100.243 |
Other Operating Expenses, Total | 0 | 0 | |||
Driftsindtægter | -100.76 | -87.09 | -46.797 | 141.445 | -103.279 |
Renteindkomst (Udgift), Netto Ikke-Drift | -2.78 | -0.802 | -14.544 | -20.676 | -20.777 |
Andre, Netto | 1.596 | 0.134 | 2.767 | 3.35 | 3.508 |
Netto Indkomst Før Skat | -101.944 | -87.758 | -58.574 | 124.119 | -120.548 |
Netto Indkomst Efter Skat | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Netto Indkomst Før Ekstra Ting | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Netto Indkomst | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Fortyndet Netto Indkomst | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Fortyndet Vægtet Gennemsnit Aktier | 165.733 | 145.652 | 110.841 | 116.747 | 105.83 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.61511 | -0.60252 | -0.52845 | 1.11466 | -1.13907 |
Fortyndet Normaliseret EPS | -0.61511 | -0.60252 | -1.71924 | 1.2741 | -1.13907 |
Totale Ekstraordinære Ting | 0 | ||||
Usædvanlig Udgift (Indkomst) | 0 | 0 | -131.988 | 28.638 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total omsætning | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
Omsætning | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
Kost af omsætning, Total | |||||
Bruttofortjeneste | |||||
Totale Driftsudgifter | 31.166 | 30.306 | 23.134 | 24.042 | 23.417 |
Salgs/Generelle/Admin. Udgifter, Total | 19.14 | 16.329 | 12.577 | 10.686 | 8.491 |
Forskning & Udvikling | 12.026 | 13.977 | 10.557 | 13.356 | 14.926 |
Driftsindtægter | -31.142 | -30.278 | -23.095 | -24.007 | -23.38 |
Renteindkomst (Udgift), Netto Ikke-Drift | -1.821 | -1.103 | -0.864 | -0.703 | -0.11 |
Andre, Netto | 1.029 | 0.887 | 0.572 | 0.123 | 0.014 |
Netto Indkomst Før Skat | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Netto Indkomst Efter Skat | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Netto Indkomst Før Ekstra Ting | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Netto Indkomst | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Fortyndet Netto Indkomst | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
Fortyndet Vægtet Gennemsnit Aktier | 189.014 | 188.98 | 174.904 | 149.616 | 149.15 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
Usædvanlig Udgift (Indkomst) | 0 |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 140.866 | 88.921 | 157.719 | 337.754 | 173.324 |
Likvider og Kortsigtede Investeringer | 138.357 | 86.743 | 152.275 | 271.659 | 160.052 |
Likvider & Lignende | 46.345 | 64.065 | 126.263 | 36.112 | 80.386 |
Kortsigtede Investeringer | 92.012 | 22.678 | 26.012 | 235.547 | 79.666 |
Totale Tilgodehavender, Netto | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
Accounts Receivable - Trade, Net | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
Prepaid Expenses | 2.481 | 2.164 | 5.049 | 5.32 | 2.668 |
Total Assets | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
Property/Plant/Equipment, Total - Net | 4.371 | 3.476 | 1.495 | 15.747 | 15.865 |
Property/Plant/Equipment, Total - Gross | 8.355 | 8.329 | 7.31 | 77.488 | 75.871 |
Accumulated Depreciation, Total | -3.984 | -4.853 | -5.815 | -61.741 | -60.006 |
Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
Intangibles, Net | 0 | 19.716 | 50.119 | ||
Other Long Term Assets, Total | 4.519 | -0.031 | 0.031 | -0.045 | 0.285 |
Total Current Liabilities | 23.172 | 22.124 | 46.806 | 65.341 | 36.751 |
Accounts Payable | 10.395 | 9.152 | 5.469 | 12.178 | 17.759 |
Accrued Expenses | 12.373 | 10.469 | 29.691 | 42.151 | 14.482 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 11.646 | 11.012 | 1.115 | |
Other Current Liabilities, Total | 0.404 | 2.503 | 0 | 3.395 | |
Total Liabilities | 77.175 | 23.314 | 47.417 | 300.614 | 310.541 |
Total Long Term Debt | 48.579 | 0 | 0 | 234.171 | 243.887 |
Long Term Debt | 48.579 | 0 | 234.171 | 243.887 | |
Deferred Income Tax | 0 | 6.014 | |||
Other Liabilities, Total | 5.424 | 1.19 | 0.611 | 1.102 | 23.889 |
Total Equity | 117.124 | 113.595 | 156.371 | 117.101 | -26.405 |
Common Stock | 0.189 | 0.15 | 0.142 | 0.106 | 0.106 |
Additional Paid-In Capital | 1709.14 | 1608.75 | 1561.1 | 1462.17 | 1447.95 |
Retained Earnings (Accumulated Deficit) | -1589.72 | -1487.78 | -1400.02 | -1341.44 | -1471.58 |
Treasury Stock - Common | -2.061 | -7.518 | -4.843 | -3.817 | -2.876 |
Other Equity, Total | -0.428 | -0.01 | -0.006 | 0.084 | -0.012 |
Total Liabilities & Shareholders’ Equity | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
Total Common Shares Outstanding | 188.726 | 148.917 | 141.496 | 106.272 | 105.926 |
Total Inventory | 0 | 4.243 | 4.68 | ||
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 109.546 | 140.866 | 139.063 | 64.898 | 88.431 |
Likvider og Kortsigtede Investeringer | 105.937 | 138.357 | 136.203 | 61.968 | 86.502 |
Likvider & Lignende | 26.001 | 46.345 | 18.834 | 21.45 | 59.52 |
Kortsigtede Investeringer | 79.936 | 92.012 | 117.369 | 40.518 | 26.982 |
Totale Tilgodehavender, Netto | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
Accounts Receivable - Trade, Net | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
Prepaid Expenses | 3.348 | 2.481 | 2.821 | 2.896 | 1.892 |
Total Assets | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
Property/Plant/Equipment, Total - Net | 8.627 | 4.371 | 8.032 | 2.835 | 3.242 |
Property/Plant/Equipment, Total - Gross | 6.303 | 8.355 | 6.109 | 6.105 | 6.104 |
Accumulated Depreciation, Total | -4.096 | -3.984 | -5.177 | -5.07 | -4.962 |
Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
Other Long Term Assets, Total | 4.519 | 0.047 | 0.049 | -0.038 | |
Total Current Liabilities | 20.371 | 23.172 | 18.445 | 16.862 | 18.905 |
Accounts Payable | 10.311 | 10.395 | 9.427 | 7.347 | 9.321 |
Accrued Expenses | 9.576 | 12.373 | 8.299 | 9.038 | 8.864 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Total Liabilities | 74.67 | 77.175 | 47.667 | 41.495 | 43.48 |
Total Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
Other Liabilities, Total | 5.454 | 5.424 | 5.438 | 1.002 | 1.098 |
Total Equity | 88.046 | 117.124 | 144.018 | 70.83 | 92.698 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.19 | 0.189 | 0.189 | 0.15 | 0.15 |
Additional Paid-In Capital | 1712.56 | 1709.14 | 1705.61 | 1608.73 | 1605.9 |
Retained Earnings (Accumulated Deficit) | -1621.65 | -1589.72 | -1559.23 | -1535.84 | -1511.25 |
Treasury Stock - Common | -2.885 | -2.061 | -2.061 | -2.061 | -2.061 |
Other Equity, Total | -0.163 | -0.428 | -0.491 | -0.15 | -0.037 |
Total Liabilities & Shareholders’ Equity | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
Total Common Shares Outstanding | 189.562 | 188.726 | 188.726 | 149.626 | 149.594 |
Other Current Liabilities, Total | 0.484 | 0.404 | 0.719 | 0.477 | 0.72 |
Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
Likvider Fra Driftsaktiviteter | -88.851 | -87.017 | -142.969 | 113.807 | -148.607 |
Likvider Fra Driftsaktiviteter | 0.427 | 0.292 | 2.934 | 3.654 | 3.683 |
Deferred Taxes | 0 | 0 | -6.014 | 0 | |
Ikke-Likvide Ting | 12.264 | 10.68 | -118.408 | 44.321 | 13.032 |
Likvid Rente Betalt | 2.289 | 0.799 | 17.353 | 19.211 | 16.465 |
Ændringer i Driftskapital | 0.402 | -10.231 | 31.079 | -58.287 | -44.774 |
Likvider fra Investeringsaktiviteter | -71.078 | 2.11 | 380.756 | -155.855 | 169.576 |
Kapitaludgifter | -1.326 | -1.221 | -0.087 | -0.07 | -0.095 |
Andre Investerings-Cash-Flow-Ting, Total | -69.752 | 3.331 | 380.843 | -155.785 | 169.671 |
Likvider fra Financieringsaktiviteter | 142.209 | 22.709 | -147.636 | -2.226 | -2.244 |
Udstedelse (Pensionering) af Aktier, Netto | 93.341 | 34.409 | 68.944 | -0.941 | -0.24 |
Udstedelse (Pensionering) af Gæld, Netto | 48.868 | -11.7 | -216.58 | -1.285 | -2.004 |
Netto Ændring i Likviditet | -17.72 | -62.198 | 90.151 | -44.274 | 18.725 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -31.934 | -101.944 | -71.45 | -48.063 | -23.476 |
Cash From Operating Activities | -31.613 | -88.851 | -67.282 | -47.843 | -23.421 |
Cash From Operating Activities | 0.112 | 0.427 | 0.324 | 0.216 | 0.109 |
Non-Cash Items | 3.68 | 12.264 | 8.648 | 5.783 | 2.797 |
Cash Interest Paid | 1.556 | 2.289 | 1.281 | 0.634 | 0.085 |
Changes in Working Capital | -3.471 | 0.402 | -4.804 | -5.779 | -2.851 |
Cash From Investing Activities | 12.093 | -71.078 | -95.252 | -18.056 | -4.408 |
Capital Expenditures | -0.248 | -1.326 | -0.08 | -0.076 | -0.076 |
Other Investing Cash Flow Items, Total | 12.341 | -69.752 | -95.172 | -17.98 | -4.332 |
Cash From Financing Activities | -0.824 | 142.209 | 117.303 | 23.284 | 23.284 |
Issuance (Retirement) of Stock, Net | -0.824 | 93.341 | 93.404 | -0.864 | -0.864 |
Issuance (Retirement) of Debt, Net | 0 | 48.868 | 23.899 | 24.148 | 24.148 |
Net Change in Cash | -20.344 | -17.72 | -45.231 | -42.615 | -4.545 |
Deferred Taxes |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Artal International S.C.A. | Investment Advisor | 45.506 | 86262020 | 0 | 2023-03-31 | LOW |
BVF Partners L.P. | Hedge Fund | 8.5192 | 16149179 | 0 | 2023-03-31 | LOW |
Ulys, L.L.C. | Investment Advisor | 2.7979 | 5303814 | 0 | 2022-08-01 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.792 | 5292626 | 43032 | 2023-03-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.7644 | 5240247 | -11438 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6709 | 5062976 | -201281 | 2023-03-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.8549 | 3516214 | 0 | 2023-03-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 1.6081 | 3048374 | 56229 | 2023-03-31 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.5515 | 2940997 | -136976 | 2023-03-31 | LOW |
New Enterprise Associates (NEA) | Venture Capital | 1.2567 | 2382286 | 0 | 2023-03-31 | LOW |
Pinnacle Associates Ltd. | Investment Advisor/Hedge Fund | 1.0235 | 1940224 | 7447 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9102 | 1725409 | 117468 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8251 | 1564098 | 47623 | 2023-03-31 | LOW |
Coats Lonnel | Individual Investor | 0.3927 | 744359 | 158356 | 2023-02-28 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 0.38 | 720243 | 0 | 2023-03-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.3794 | 719182 | 306384 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.3633 | 688611 | -7329 | 2023-03-31 | LOW |
Parkman Healthcare Partners LLC | Hedge Fund | 0.3563 | 675328 | 254126 | 2023-03-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.3561 | 675018 | -19915 | 2023-03-31 | LOW |
Asset Management One Co., Ltd. | Investment Advisor/Hedge Fund | 0.3194 | 605528 | 605528 | 2022-08-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lexicon Company profile
Om Lexicon
Lexicon Pharmaceuticals, Inc. er en biofarmaceutisk virksomhed. Virksomheden fokuserer på opdagelse, udvikling og markedsføring af farmaceutiske produkter til behandling af sygdomme hos mennesker. Virksomhedens pipeline omfatter Sotagliflozin, LX9211 og LX2761. Sotagliflozin er et lille molekylært stof til oral indgivelse, som er under udvikling til behandling af hjertesvigt og type I-diabetes samt type II-diabetes, hjertesvigt og kronisk nyresygdom. LX9211 er et lille molekylært stof, der gives oralt, og som er under udvikling til behandling af neuropatiske smerter. Selskabet gennemfører et klinisk fase II-forsøg med LX9211 til behandling af diabetiske perifere neuropatiske smerter og et andet klinisk fase II-forsøg med LX9211 til behandling af postherpetisk neuralgi. LX2761 er et lille molekylært stof til oral indgivelse, der er designet til at hæmme natrium-glukose cotransporter 1 (SGLT1) lokalt i mave-tarmkanalen uden nogen hæmning af natrium-glukose cotransporter 2 (SGLT2) i nyrerne.
Industry: | Bio Therapeutic Drugs |
8800 Technology Forest Place
8800 Technology Forest Place
77381
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com